Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations

Article English OPEN
Arteaga, A. ; Dhand, N.K. ; McCann, T. ; Knottenbelt, C.M. ; Tebb, A.J. ; Evans, H. ; Eckersall, P.D. ; Ramsey, I.K. (2010)

<b>Background</b>: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs.\ud \ud <b>Objectives</b>: To assess whether control of hyperadrenocorticism (HAC) affects the concentrations of Hp, CRP, SAA, alkaline phosphatase (ALKP) and cholesterol, to determine whether these analytes can be used to assess control of HAC following trilostane treatment, and whether a combination of these tests offers a valid method of assessing disease control.\ud \ud <b>Methods</b>: Hp, CRP, SAA, ALKP and cholesterol were assessed in 11 dogs with spontaneous HAC before and after treatment with trilostane. Adequate control of HAC was defined as post-ACTH cortisol less than 150 nmol/l.\ud \ud <b>Results</b>: Significant reductions in Hp, ALKP, cholesterol and SAA (P&#60;0·05) but not of CRP were found after control of HAC. Only Hp, cholesterol and ALKP were moderately informative (Se &#38; Sp&#62;0·7) of disease control when compared to adrenocorticotropin or corticotropin (ACTH) stimulation test. SAA and CRP were unhelpful (Se &#38; Sp&#60;0·7). The analysis of the combination of the analytes did not improve the correlation with ACTH stimulation test.\ud \ud <b>Clinical Relevance</b>: Relying on these analytes does not provide additional information over ACTH stimulation test results when assessing control of HAC treated with trilostane.
  • References (26)
    26 references, page 1 of 3

    3. Braddock JA, Church DB, Robertson ID, Watson ADJ. (2003) Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Australian Veterinary Journal 8, 600-607

    4. Ceron JJ, Eckersall PD, Martinez-Subiela S. (2005) Acute phase proteins in dogs and cats: current knowledge and future perspectives. Veterinary Clinical Pathology 34, 85-99

    5. Child JA, Cooper Eh, Illingworth S, Worthy TS. (1978) Biological markers in Hodgkin's disease and non-Hodgkin's lymphoma. Recent Results in Cancer Research 64, 180-189

    6. Dohoo, I. R., S. W. Martin, and H. Stryhn. (2003) Veterinary Epidemiologic Research. 1st ed, Charlottetown, PEI, Canada, AVC

    7. Dunn KJ, Herrtage RME, Dunn JK. (1995) Use of ACTH stimulation test to monitor treatment of canine hypereadrenocorticism. Veterinary Record 137, 161-175 v i

    8. Eckersall PD, Duthie S, Safi S, eMoffat D, Horadagoda NU, Doyle S, Parton R, w Bennet D & Fitzpatrick JL (1999a) An automated biochemical assay for Haptoglobin: prevention of interference from Calbumin. Comparative haematology International 9, 117-124. o p 9..Eckersall PD, Duthie S, Toussaint JM, Gruys E, Heeygaard P, Alava M, Lipperheide C, Madec F. (1999) Standarization of diagnostic assays for animal acute phase proteins. Advances in Veterinary Medicine 41, 643-655

    10. Feldman EC, Nelson RW. (2004) Canine hyperadrenocorticism (Cushing's syndrome). In: Canine and feline endocrinology and reproduction. 3rd edn. Eds E.C. Feldman and R.W. Nelson RW. W.B. Saunders; St. Louis pp 252-358

    11. Greiner M, Pfeiffer D, Smith RD. (2000) Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests Preventive Veterinary Medicine 45,23-41

    12. Harvey JW, West CL. (1987) Prednisolone-induced increases in serum alpha-2- globulin and Haptoglobin concentration in dogs. Veterinary Pathology 24, 90-92

    17. Ling GV, Stabenfeldt GH, Comer KM, Gribble DH, Schechter RD. (1979) Canine hyperadrenocorticism: Pretreatment clinical and laboratory evaluation of 117 cases. Journal of the American Veterinary Medicine Association 174, 1211-1214

  • Similar Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark